No Data
Helios - For the fiscal year ending December 2024, significant revenue growth is expected, and research and development will be promoted in the fields of somatic stem cell regenerative Pharmaceuticals and iPSC regenerative Pharmaceuticals.
Helios <4593> announced its consolidated financial results (IFRS) for the fiscal year ending December 2024 on the 14th.
Fanpepp --- In the fiscal year ending December 2024, research and development will be advanced focusing on antibody-inducing peptide projects and functional peptides.
Fanpep Co., Ltd. <4881> announced its consolidated financial results for the fiscal year ending December 2024 on the 12th. Revenue was 0.006 billion yen (compared to 0 billion yen in the previous period), operating loss was 0.901 billion yen (compared to 0.994 billion yen in loss), ordinary loss was 0.896 billion yen (compared to 0.94 billion yen in loss), and net loss attributable to the Shareholder for the current period was 0.889 billion yen (compared to 0.933 billion yen in loss). In the antibody-inducing peptide project, the antibody-inducing peptide "FPP003" (target protein: IL-17A) is discussed.
Poxel Announces Results of Its Combined General Meeting Held on February 11, 2025
The Nikkei average is up by about 110 yen, with Renesas, Nippon Electric Glass, and Nomura among the top performers in terms of stock price increase.
On the 6th at 11:02 AM, the Nikkei average stock price was trading around 38,940 yen, about 110 yen higher than the previous day. In the morning, following the rise in US stocks on the 5th, it reached a high of 39,190 yen and 13 sen at 9:29 AM, up 358 yen and 65 sen. After that, due to selling while waiting for a bounce back, coupled with the Foreign Exchange market showing about 152 yen per dollar, which is a stronger yen compared to the morning levels, the market experienced heavy movement at higher levels. Among the stocks included in the Nikkei average, Renesas is among the top gainers.
Stocks that moved the previous day part 1: Sumitomo Electric, SANKYO, Yamagata Bank, ETC.
Stock name <code> Closing price on the 4th ⇒ Comparison with the previous day Sumitomo Electric <5802> 3009 +224 The financial estimates for the fiscal year ending March 2025 have been revised upwards. SANKYO <6417> 2288 +209 The financial estimates and dividends for the fiscal year ending March 2025 have been revised upwards. RoboHome <1435> 138 +12 Commemorative shareholder benefits for the 10th anniversary of being listed. Sumitomo Corporation <8053> 3489 +183 Pre-tax profit for the cumulative third quarter increased by 4.4%, reversing from a 5.1% decrease in the first half. Reprocell <4978> 156 +
Sumitomo Pharma Returns to Profit in Nine Months to December 2024